A phase 2, open-label, randomized, multiple-dose study evaluating Inarigivir in treatment-naïve patients with chronic hepatitis B.
Yuen MF, Chen CY, Liu CJ, Jeng WJ, Elkhashab M, Coffin CS, Kim W, Greenbloom S, Ramji A, Lim YS, Kim YJ, Fung SK, Kim DJ, Jang JW, Lee KS, Iyer RP, Macfarlane C, Jackson K, Locarnini SA, Chan HLY, Afdhal NH.
Yuen MF, et al. Among authors: iyer rp.
Liver Int. 2023 Jan;43(1):77-89. doi: 10.1111/liv.15465. Epub 2022 Nov 11.
Liver Int. 2023.
PMID: 36300646
Clinical Trial.